Latest Period
Q4 2025
Security Snapshot
Eledon Pharmaceuticals, Inc. - Common Stock (ELDN) Institutional Ownership
CUSIP: 28617K101
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
94
Shares (Excl. Options)
44,151,094
Price
$1.51
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- ELDN on Nasdaq
- Shares outstanding
- 75,532,017
- Price per share
- $3.22
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 44,151,094
- Total reported value
- $66,693,038
- % of total 13F portfolios
- 0%
- Share change
- +4,306,723
- Value change
- -$4,537,335
- Number of holders
- 94
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ELDN - Eledon Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 28617K101.
- 94 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 94 to 85 between Q4 2025 and Q1 2026.
- Reported value moved from $66,693,038 to $68,323,778.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 94 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 28617K101?
CUSIP 28617K101 identifies ELDN - Eledon Pharmaceuticals, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 28617K101:
Significant Owners of Eledon Pharmaceuticals, Inc. - Common Stock (ELDN) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5.8% | +24% | $13,493,040 | +$2,325,502 | 4,380,857 | +21% | BlackRock, Inc. | 31 Mar 2026 |
| Coastlands Capital LP | 5% | -16% | $6,733,682 | -$1,410,519 | 3,937,826 | -17% | Coastlands Capital LP | 31 Dec 2025 |
| ARMISTICE CAPITAL, LLC | 5% | $10,259,798 | 3,137,553 | Armistice Capital, LLC | 31 Dec 2024 | |||
| Frazier Life Sciences Public Fund, L.P. | 2% | $3,847,923 | 1,176,735 | James N. Topper | 31 Dec 2024 |
As of 31 Dec 2025, 94 institutional investors reported holding 44,151,094 shares of Eledon Pharmaceuticals, Inc. - Common Stock (ELDN). This represents 58% of the company’s total 75,532,017 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Eledon Pharmaceuticals, Inc. - Common Stock (ELDN) together control 55% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BVF INC/IL | 8.3% | 6,293,282 | 0% | 0.32% | $9,502,856 |
| VANGUARD GROUP INC | 5.3% | 4,039,686 | +24% | 0% | $6,099,926 |
| BlackRock, Inc. | 4.8% | 3,627,208 | +4.7% | 0% | $5,477,084 |
| Defilade Capital Management, L.P. | 4.4% | 3,290,450 | 0% | 0.67% | $4,968,580 |
| Ensign Peak Advisors, Inc | 3.3% | 2,464,919 | +95% | 0.01% | $3,722,028 |
| Zimmer Partners, LP | 3.2% | 2,384,228 | +31% | 0.09% | $3,600,184 |
| SPHERA FUNDS MANAGEMENT LTD. | 2.8% | 2,132,131 | +67% | 0.67% | $3,219,518 |
| Blue Owl Capital Holdings LP | 2.6% | 1,929,912 | +97% | 0.9% | $2,914,167 |
| ADAR1 Capital Management, LLC | 2.4% | 1,821,812 | 0.21% | $2,750,936 | |
| Jefferies Financial Group Inc. | 2.1% | 1,580,625 | 0.02% | $2,386,744 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 1,421,617 | +3.8% | 0% | $2,146,964 |
| Catalio Capital Management, LP | 1.7% | 1,259,820 | +19% | 0.36% | $1,902,328 |
| AWM Investment Company, Inc. | 1.5% | 1,100,000 | 0.16% | $1,661,000 | |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1.4% | 1,039,275 | 0.24% | $1,569,305 | |
| Stonepine Capital Management, LLC | 1.2% | 893,100 | 1.1% | $1,348,581 | |
| Sanofi | 1.1% | 814,980 | 0% | 0.4% | $1,230,620 |
| STATE STREET CORP | 1% | 773,885 | +18% | 0% | $1,168,566 |
| CM Management, LLC | 0.86% | 650,000 | +8.3% | 0.83% | $981,500 |
| 22NW, LP | 0.84% | 636,364 | 0% | 0.74% | $960,910 |
| SG Americas Securities, LLC | 0.83% | 627,392 | 0% | $947,000 | |
| UBS Group AG | 0.79% | 593,131 | +535% | 0% | $895,628 |
| Caligan Partners LP | 0.74% | 555,978 | 0.08% | $839,527 | |
| JANE STREET GROUP, LLC | 0.65% | 489,376 | +151% | 0% | $738,958 |
| NORTHERN TRUST CORP | 0.57% | 429,813 | +0.29% | 0% | $649,018 |
| Focus Partners Wealth | 0.42% | 317,443 | 0% | $479,339 |
Institutional Holders of Eledon Pharmaceuticals, Inc. - Common Stock (ELDN) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 22,186,978 | $68,323,778 | -$2,676,409 | $3.08 | 85 |
| 2025 Q4 | 44,151,094 | $66,693,038 | -$4,537,335 | $1.51 | 94 |
| 2025 Q3 | 36,469,559 | $94,453,818 | -$12,219,070 | $2.59 | 82 |
| 2025 Q2 | 40,843,175 | $110,685,079 | +$5,557,133 | $2.71 | 85 |
| 2025 Q1 | 38,448,901 | $130,340,726 | -$2,283,033 | $3.39 | 83 |
| 2024 Q4 | 38,479,556 | $158,542,263 | +$81,995,653 | $4.12 | 75 |
| 2024 Q3 | 18,485,827 | $46,028,922 | +$410,879 | $2.49 | 33 |
| 2024 Q2 | 18,259,810 | $48,206,187 | +$22,892,459 | $2.64 | 31 |
| 2024 Q1 | 9,595,061 | $19,765,324 | +$914,973 | $2.06 | 28 |
| 2023 Q4 | 9,153,168 | $16,475,058 | +$507,102 | $1.80 | 28 |
| 2023 Q3 | 8,917,722 | $12,217,005 | -$186,914 | $1.37 | 28 |
| 2023 Q2 | 9,275,200 | $12,707,758 | +$2,932,975 | $1.37 | 32 |
| 2023 Q1 | 6,240,661 | $14,727,632 | -$15,081 | $2.36 | 29 |
| 2022 Q4 | 6,249,494 | $14,377,182 | -$299,603 | $2.28 | 27 |
| 2022 Q3 | 6,267,437 | $17,296,971 | -$726,076 | $2.76 | 26 |
| 2022 Q2 | 6,534,650 | $15,944,119 | -$1,242,145 | $2.44 | 27 |
| 2022 Q1 | 7,004,967 | $27,598,192 | -$4,350,190 | $3.94 | 30 |
| 2021 Q4 | 7,884,710 | $34,745,775 | -$3,532,209 | $4.41 | 34 |
| 2021 Q3 | 8,434,281 | $52,121,569 | -$6,530,652 | $6.18 | 29 |
| 2021 Q2 | 9,423,304 | $74,527,000 | +$5,445,356 | $7.91 | 29 |
| 2021 Q1 | 8,317,680 | $88,956,000 | +$88,566,000 | $10.70 | 32 |
| 2020 Q4 | 36,111 | $556,000 | +$556,000 | $15.40 | 1 |